A meta-analysis led by Chengliang Yang from the University of British Columbia reviewed data from 4566 adults to evaluate the cardiac safety of remdesivir in COVID-19 patients. The study found no significant increase in cardiac adverse events (CAEs) among those treated with remdesivir compared to standard care, with a pooled risk ratio of 0.84. Despite 6.6% of patients experiencing CAEs, no substantial differences were recorded across demographics or comorbidities. The authors concluded that remdesivir does not elevate the risk of cardiac complications in this patient population, though further investigation is necessary.
Source: BMJ Open